Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda — or at least the items we can remember — our rather modest. We plan to catch up on some reading, take several naps, and stroll about town. And what about you? This is a lovely time of year to enjoy the great outdoors. You could pick a few apples or, if you feel brave, search for The Great Pumpkin. You could make time for someone special or, if you prefer, research your health plan for next year. For the mischievous among you, perhaps wager a bet on which country that certain someone in the White House will next ask for help in probing political rivals. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.

When Congress passed a drug pricing bill last week that will save the government $3 billion — the first such bill passed in nearly a year — no one really noticed, STAT notices. There was no press conference from the bill sponsors, no snarky reaction from the drug industry, virtually no press release from any of the advocacy organizations that champ at the bit to weigh in on every twist and turn of the ongoing drug pricing debate in Washington. But the bill would change the way discounts are calculated for authorized generics in the Medicaid program.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!